QIAGEN reports full results for second quarter and first half of 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Qiagen (QGEN) Reports In-Line Q2 EPS; Offers FY19 EPS Outlook
July 30, 2019 4:13 PM EDTQiagen (NYSE: QGEN) reported Q2 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $381.6 million versus the consensus estimate of $382.2 million.
QIAGEN delivers on Q2 2019 outlook (unchanged from July 24 announcement)Net sales of $381.6 million (+1% actual, +5% at constant exchange rates, or CER vs. ~5% CER outlook)Diluted EPS of $0.19; adjusted EPS $0.33 ($0.34 CER vs. ~$0.33-0.34 CER outlook)Sample to Insight portfolio developmentsQuantiFERON-TB up 6% CER in line with outlook, on track for >15% CER growthTwo FDA approvals to date in 2019 for novel therascreen companion... More